Diagnostically compatible live attenuated Brucellosis vaccine
This technology is a live-attenuated vaccine designed to prevent Brucellosis, a serious infectious disease that jumps from livestock to humans. Researchers created a weakened version of the Brucella bacteria by deleting a specific gene (tspA) responsible for a crucial protein-processing enzyme. Because the bacteria can no longer produce this enzyme, they cannot cause full-blown disease but still trigger a robust immune response in the host. This approach offers a way to vaccinate animals—and potentially humans—using a recombinant strain that is safer than traditional live vaccines.
What you could build
A veterinary vaccine product line for cattle, sheep, and goats in regions where Brucellosis is endemic, sold to livestock producers and government agricultural agencies.
Who in Virginia should care
Relevant to Virginia’s large cattle and livestock industry and researchers at the Virginia-Maryland College of Veterinary Medicine.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Aloka B. Bandara, Stephen M. Boyle, Nammalwar Sriranganathan, Gerhardt G. Schurig
- Granted
- April 29, 2008
- Status
- Granted patent
- Patent number
- 7364745
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.